Plastic and nonmetallic article shaping or treating: processes – Formation of solid particulate material directly from molten... – By vibration or agitation
Reexamination Certificate
2001-03-30
2003-07-22
Theisen, Mary Lynn (Department: 1732)
Plastic and nonmetallic article shaping or treating: processes
Formation of solid particulate material directly from molten...
By vibration or agitation
C264S005000, C264S007000, C425S006000, C425S010000
Reexamination Certificate
active
06596206
ABSTRACT:
TECHNICAL FIELD
This invention relates generally to the generation of pharmaceutical agent particles, and more particularly relates to the use of focused acoustic energy in generating solid particles comprised of a pharmaceutical agent.
BACKGROUND
Rapid and efficient production of particles, particularly small and/or substantially uniform particles, is needed in a variety of industries. Among other advantages, small, substantially uniform particles possess favorable flow characteristics and exhibit little variation in interparticle behavior. In the pharmaceutical industry, for example, the particle size of a therapeutic agent can affect the dissolution rate, bioavailability and overall stability of the agent in a formulation. Precise control of the particle size of therapeutic agents is particularly important for sustained release applications, where the rate of drug release is related to the size of a particle containing the drug. In addition, pulmonary delivery of a therapeutic agent requires specifically sized particles, generally on the order of about 1 &mgr;m to about 7 &mgr;m. Particles that are too large may be deposited within the throat, while particles that are too small will be exhaled. Thus, the ability to produce small, uniform particles of a therapeutic agent is critically important in the development of particulate pharmaceutical products.
Various approaches for attaining small and uniform particles have been used. Conventional comminution techniques, e.g., crushing, grinding and milling, rely on mechanical forces to break apart relatively large particles into smaller particles. Air-jet mills and other mills, available from, for example, DT Industries, Bristol, Pa., under the tradename STOKES®, are commonly used by the pharmaceutical industry to decrease the particle size of a bulk therapeutic agent into a range suitable for pharmaceutical applications. One drawback to such mechanical comminution techniques, however, is that some therapeutic agents, particularly proteins and other therapeutic biomolecules, are damaged during the process. Another drawback of mechanical comminution is the wide distribution of particle sizes produced by these techniques. Among other problems, large variations in the size of particles limit the ability to produce sustained-release formulations and waste large amounts of therapeutic agents intended, for example, for inhalation. Although sieving a comminuted therapeutic agent through an appropriate mesh screen provides a more narrow particle size distribution, large quantities of particles not having the desired size are wasted and the potential for contamination is increased, as the therapeutic agent must contact additional surfaces.
Other techniques for producing pharmaceutical particles include conventional recrystallization methods. In such methods, the therapeutic agent is initially dissolved in a suitable solvent. In one approach, the temperature of the solution is changed so that the solubility of the solute is decreased. In another approach, a second solvent, an “antisolvent,” is added so that the solubility of the solute is decreased. In both approaches, the solute precipitates or crystallizes out of the solution due to reduced solubility in the altered solution. These methods, however, often require toxic solvents, result in wet particles (that require further processing, e.g., drying), and may produce particles having variable sizes.
Supercritical fluid technology has solved some of these problems. One method for using this relatively new technology is called the rapid expansion of supercritical solutions or “RESS” method. See Tom et al. (1991)
Biotechnol. Prog.
7(5):403-411. In the RESS method, the solute of interest, e.g., a pharmaceutical agent, is first solubilized in a supercritical fluid, i.e., a fluid at a temperature and pressure greater than its critical temperature (T
c
) and critical pressure (P
c
) Generally, the supercritical fluid is carbon dioxide, although other fluids are available. The solution is then rapidly passed through a nozzle that is connected to a relatively low-pressure medium. The sudden depressurization of the solution as it passes into the relatively low-pressure medium causes the supercritical fluid to expand, i.e., the density of the supercritical fluid decreases, reducing the ability of the supercritical fluid to solubilize the therapeutic agent. As a direct consequence of the reduced solubility, a supersaturated solution develops, which, in turn, causes the solute agent to precipitate or crystallize out in very small particles.
A variation of this idea is to prepare a solution of a therapeutic drug in a conventional solvent, and then spray the solution through a nozzle into a supercritical fluid that acts as an anti-solvent. When the two fluids make contact, a rapid volume expansion occurs, reducing solvent density and solvent capacity, in turn increasing supersaturation, solute nucleation and particle formulation. This method is commonly referred to as gas anti-solvent recrystallization or “GAS.” See, for example, Debenedetti et al. (1993)
J. Control. Release
24:27-44 and PCT WO 00/37169 to Merrifield. This process has been applied to various proteins to produce particle sizes of about 5 &mgr;m. See European Patent No. 0 542 314.
Although use of supercritical fluid technology offers the capability of producing relatively small particles of uniform size, it is not without drawbacks. One problem associated with these supercritical methods is the reliance on nozzles and tubes for delivering the solutions. Nozzles are known to wear down over time, altering the geometry of the equipment and affecting the size of the droplets formed. In addition, nozzles may become blocked during use, when, for example, particles agglomerate upon rapid expansion within the nozzle bore. In addition, nozzles and associated components require cleaning and may contaminate solutions when not properly maintained.
Furthermore, the droplet sizes of the solutions (both supercritical and conventional solutions) produced by methods relying on nozzles are relatively varied. As a result there will be a large variance of the surface tension between droplets of different sizes. At the sizes required for supercritical methods, the differences in surface tension between droplets causes large variations in crystallization kinetics and growth. These differences result in differently sized particles. Although U.S. Pat. No. 5,874,029 to Subramaniam et al. discusses methods for producing small-sized droplets using nozzles, the methods still suffer from the inability to effectively and consistently produce droplets of uniform size.
Thus, there is a need in the art for an improved particle formation technique wherein particle formation is highly reproducible, controllable and predictable, and substantially uniform particle size can be achieved. An ideal method would minimize or eliminate contact of the particle-forming fluid(s) with surfaces of process equipment or contaminants adsorbed thereon. The present invention addresses the aforementioned need in the art by using focused acoustic energy to eject particle-forming droplets from a pharmaceutical agent solution.
SUMMARY OF THE INVENTION
Accordingly, it is a primary object of the invention to address the aforementioned need in the art by providing a novel method and device for generating pharmaceutical agent particles using focused acoustic ejection technology.
Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.
In one aspect, then, the invention provides a method and device for generating solid particles of pharmaceutical agents using focused acoustic energy. A solution of the pharmaceutical agent is provided in a solvent, which may be an aqueous fluid, a nonaqueous fluid, or a supercritical fluid. Focused acoustic energy is used to eject a droplet of the soluti
Picoliter Inc.
Reed Dianne E.
Reed & Eberle LLP
Theisen Mary Lynn
LandOfFree
Generation of pharmaceutical agent particles using focused... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Generation of pharmaceutical agent particles using focused..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Generation of pharmaceutical agent particles using focused... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3058388